Drug Trial Radar · NCT04227990
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
Last checked: Nov 19, 2026Latest source record: Jan 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Nov 27, 2017
Primary completion
Oct 15, 2018
Study completion Jan 3, 2019
Sponsor
- Lead sponsor
- BeyondSpring Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to compare the duration of severe neutropenia (DSN) in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + monotheray plinabulin or combination plinabulin/pegfilgrastim Severe neutropenia is an absolute neutrophil count (ANC) \<0.5 × 10\^9/L. Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study.
Conditions
- Chemotherapy-induced Neutropenia
Interventions
PlinabulinDrug
Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
PegfilgrastimDrug
Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Docetaxel, doxorubicin, and cyclophosphamide (TAC)Drug
Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of Severe Neutropenia (DSN)Time frame: Cycle 1 (21 days)
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Cancer Center of Guangzhou Medical University Breast Oncology
Guangzhou, Guangzhou, China
Harbin Medical University Cancer Hospital
Harbin, Harbin, China
Fourth Hospital of Hebei Medical University Breast cancer department
Shijiazhuang, Hebei, China
China-Japan Union Hospital of Jilin University Tumor department of Hematology
Changchun, Jilin, China
Liaoning Cancer Hospital & Institute
Shenyang, Shenyang, China
Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department
Dnipro, Ukraine
Prykarpatskiy Regional Oncological Center
Ivano-Frankivsk, Ukraine
"V.T. Zaycev Institute of General and Urgent Surgery NAMS of Ukraine Dept. of Oncology
Kharkiv, Ukraine
Kirovograd Regional Oncological Center
Kropyvnytskyi, Ukraine
Public Institution Kryvyi Rih Oncology Center
Krutyi Bereh, Ukraine
Odessa regional clinical hospital Thoracic Surgery Department Academician Zabolotnoho
Odesa, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.